 Scaling The Peaks Biotech Stocks Hitting 52-week Highs Aug. 11 Allovir Inc NASDAQ: ALVR Erytech Pharma SA NASDAQ: ERYP Eyenovia Inc NASDAQ: EYEN announced an exclusive collaboration and licensing agreement for MicroLine and MicroPine in Greater China and South Korea Evoke Pharma Inc NASDAQ: EVOK Fortress Biotech NASDAQ: FBIOreacted to its second-quarter results GENMAB ASS ADR NASDAQ: GMAB Inari Medical Inc NASDAQ: NARI iTeos Therapeutics Inc NASDAQ: ITOS Kura Oncology Inc NASDAQ: KURA OncoSec Medical Inc NASDAQ: ONCS Orthopediatrics Corp NASDAQ: KIDS Pacira Biosciences Inc NASDAQ: PCRX Rocket Pharmaceuticals Inc NASDAQ: RCKT Silk Road Medical Inc NASDAQ: SILK Trevi Therapeutics Inc NASDAQ: TRVIDown In The Dumps Biotech Stocks Hitting 52-week Lows Aug. 11 Burning Rock Biotech Ltd NASDAQ: BNRannounced its second-quarter results Homology Medicines Inc NASDAQ: FIXXreacted to its second-quarter results Legend Biotech Corp NASDAQ: LEGN Nurix Therapeutics Inc NASDAQ: NRIXStocks In Focus Moderna Clinches Deal With U.S. Government to Supply 100M Doses of Coronavirus Vaccine For 1.525B Moderna Inc NASDAQ: MRNA said it has negotiated a deal to supply the U.S. government 100 million doses of mRNA-1273, its investigational vaccine against SARS-CoV2, for up to 1.525 billion.The stock rallied 11.28 to 76.75 in after-hours trading.India Globalization Gets FDA Approval For Initiating Phase 1 Trial Of CBD Medication In Alzheimers Patients India Globalization Capital, Inc. NYSE: IGC said the FDA notified on July 30 that it has authorized the company to initiate a Phase 1 human trial study for its investigational cannabinoid formulation for the treatment of patients suffering from mild to severe dementia due to Alzheimers disease.The company said it plans to begin enrolling patients suffering from Alzheimers-related dementia for a 12-subject safety Multiple Ascending Dose Study.The stock soared 73.62 to 1.11 in after-hours trading.Cellular Biomedicine to Go Private In Transaction Valued at 19.75Share Cellular Biomedicine Group Inc NASDAQ: CBMG said it has signed a definitive merger agreement to be acquired by a consortium consisting of the companys management, led by CEO Bizuo Liu, which collectively holds about 51.5 of outstanding shares, and private equity investors, for 19.75 in cash for each outstanding share of common stock.In pre-market trading Wednesday, the stock was jumping 36.30 to 19.45.Supernus Expects Q2 Revenues to Exceed Consensus Supernus Pharmaceuticals Inc NASDAQ: SUPN announced preliminary second-quarter results, expecting revenues of 126.7 million, up 21 year-over-year. Analysts estimate revenues of 89.34 million.AzurRx Announces Positive Preliminary Results From Mid-phase Study of Combo Therapy In Cystic Fibrosis AzurRx BioPharma Inc NASDAQ: AZRX announced positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis.In the primary efficacy analysis, patients receiving MS1819 in combination with PERT therapy achieved a clinically meaningful improvement in the coefficient of fat absorption CFA at each of the three dose levels, with no adverse safety events reported, AzurRx said.In after-hours trading, the stock jumped 27.38 to 1.31.Lilly, Innovent Announce Chinese Regulatory Agencys Acceptance of Application For Tyvyt Label Expansion Eli Lilly And Co NYSE: LLY and partner Innovent Biologics said that Chinese drug regulator agency, the National Medical Products Administration, accepted the sNDA for Tyvyt in combination with chemotherapy medication gemcitabine and platinum as first-line therapy in squamous non-small cell lung cancer.Earnings Cumberland Pharmaceuticals, Inc. NASDAQ: CPIX reported an increase in second-quarter net revenues from 9.4 million in 2019 to 9.6 million in 2020. Adjusted earnings per share, or EPS, increased from 5 cents to 8 cents, while analysts had estimated EPS of 3 cents.The stock gained 7.99 to 3.65 in after-hours trading.Inari Medicals second-quarter revenues fell from 27 million in 2019 to 25.4 million in 2020. The net loss per share narrowed from 17 cents to 16 cents, while analysts estimated a loss of 18 cents per share.The stock rose 6.07 to 65.90 in after-hours trading.View more earnings on IBBT2 Biosystems Inc NASDAQ: TTOO said its second-quarter revenues increased from 1.80 million in 2019 to 2.55 million in 2020. The loss per share narrowed from 35 cents to 9 cents, while analysts estimated a loss per share of 15 cents.The company guided full-year revenues to 18 million-20 million, with 60 T2Dx Instrument sales contracts expected to be received in the year. Analysts, on average, estimate revenues of 14.55 million.The stock was down 11.23 to 1.66.Offerings Pacific Biosciences of California Inc NASDAQ: PACB said it priced its previously announced underwritten public offering of 19.43 million shares of its common stock at 4.47 per share, for raising gross proceeds of about 86.9 million. The offering is expected to close on or about August 14, 2020 subject to satisfaction of customary closing conditions.The stock added 1.79 to 4.55 in after-hours trading.Seres Therapeutics Inc NASDAQ: MCRB said it is commencing an underwritten registered public offering of 8 million shares of its common stock. All of the shares in the proposed offering are to be sold by the company.The stock moved up 0.80 to 20.20 in after-hours trading.Adverum Biotechnologies Inc NASDAQ: ADVM said it has commenced an underwritten public offering of 200 million worth of its common stock.In after-hours trading, the stock was down 3.40 to 15.06.Trevena Inc NASDAQ: TRVN said it intends to offer shares of its common stock in an underwritten public offering.The stock slumped 16.79 to 2.28 in after-hours trading.On The Radar Earnings Royalty Pharma plc NASDAQ: RPRX before the market open Beam Therapeutics Inc NASDAQ: BEAM before the market open Trillium Therapeutics Inc NASDAQ: TRIL before the market open Milestone Pharmaceuticals Inc NASDAQ: MIST before the market open Ideaya Biosciences Inc NASDAQ: IDYA before the market open TELA Bio Inc NASDAQ: TELA after the market close Brickell Biotech Inc NASDAQ: BBI after the market close Dare Bioscience Inc NASDAQ: DARE after the market close Biocept Inc NASDAQ: BIOC after the market close ImmuCell Corporation NASDAQ: ICCC after the market close Eyenovia Inc NASDAQ: EYEN after the market close Eton Pharmaceuticals Inc NASDAQ: ETON after the market close Thermogenesis Holdings Inc NASDAQ: THMO after the market close OpGen Inc NASDAQ: OPGN after the market close KemPharm Inc OTC: KMPH after the market close Neoleukin Therapeutics Inc NASDAQ: NLTX after the market close Salarius Pharmaceuticals Inc NASDAQ: SLRX after the market closeSee more from Benzinga The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 23 Coronavirus Vaccine Study Starts In September The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 